DaVita Honors 25 Years of Clinical Advancement in Chronic Disease Care

Rhea-AI Summary

DaVita (NYSE:DVA), a leading kidney care provider, celebrates 25 years of its research division DaVita Clinical Research (DCR). The research arm has conducted over 500 clinical trials across 250+ research sites, with 8,900+ participants in the last 5 years. DCR has contributed to every FDA-approved ESKD drug and published 180 manuscripts and 520 research abstracts.

Notable achievements include participation in COVID-19 vaccine trials, revising nephrology standards for anemia management, and implementing decentralized recruitment services in 2024 to increase diverse patient participation. The company currently serves 283,100 patients at 3,175 outpatient dialysis centers globally, with 2,662 centers in the US and 513 centers across 13 other countries.

Largest kidney care research arm advances science to inform care delivery

DENVER, Aug. 27, 2025 /PRNewswire/ -- As part of its 25^th-anniversary celebration, DaVita, a leading provider of comprehensive kidney care, is proud to spotlight the groundbreaking work of its wholly owned research arm, DaVita Clinical Research (DCR). For a quarter-century, DCR has played a pivotal role in advancing kidney care — driving access to new therapies, improving clinical outcomes and shaping the future of nephrology through rigorous research and clinical trials.

"Clinical research has revolutionized the way we understand and treat entire disease states, including chronic kidney disease," said Jeff Giullian, MD, chief medical officer for DaVita. "I've seen firsthand how breakthroughs in research — and the contributions of DaVita Clinical Research — have enabled providers to deliver more personalized, effective care that improves patients' lives. This milestone is a reflection of DaVita's enduring commitment to science and education as drivers of a healthier future."

Rapid Response in Times of Change
DCR has consistently adapted to meet the evolving demands of healthcare, contributing to landmark efforts across the industry:

• COVID-19 response — DaVita contributed to vaccine trials and hosted one of the initial rounds of vaccinations for frontline workers at its DCR headquarters, ultimately participating in a federal effort to support access to vaccines for hundreds of thousands of at-risk patients at their existing point of care.
• Nephrology standards — Results from DaVita research have been leveraged to inform clinical practice guidelines and policy, including a revised approach to anemia management now widely adopted across the nephrology field.
• Innovations in care — DaVita's concerted focus on research enables careful review of data to identify how incremental changes, like increasing awareness of and access to home dialysis, may impact improved mortality and hospitalization rates.

"Research and data-driven insights help fuel innovation, which is the key to continuing to improve quality of care," said Francesca Tentori, MD, MSCI, vice president of outcomes research and patient empowerment for DaVita. "We're proud of the insights we've uncovered over the past 25 years, and we're excited to continue driving industry-leading outcomes research and clinical trials that advance care for individuals with kidney disease."

Research that Drives Results
DaVita has authored 180 manuscripts and 520 research abstracts or posters aimed at improving clinical outcomes in kidney care and adjacent disease states.

A 2017 study across 40 dialysis centers showed that ClearGuard HD antimicrobial barrier caps significantly reduce bloodstream infections for patients with central venous catheters (CVCs), improving outcomes at scale. CVCs can contribute disproportionately to bloodstream infection and, by extension, to infection-related hospitalization, mortality and morbidity in dialysis patients. The findings from this study yielded an important breakthrough, driving learnings across the nephrology community that helped improve patient outcomes at scale.

The most recent example is a forthcoming oral presentation to be presented at the American Society of Nephrology Kidney Week in November illustrating the association between GLP-1 drugs and hospitalization rates for people with kidney failure. This research originated from DaVita's program inviting independent medical directors to submit research ideas, ensuring studies reflect the real-world perspectives of prescribing nephrologists.

Clinical Trials that Advance Therapies 
As the largest U.S. trial network for chronic kidney disease (CKD) and end stage kidney disease (ESKD), DCR leverages its broad reach and deep expertise to conduct impactful trials efficiently.

"By expanding our global research network, we're accelerating innovation and creating new opportunities to advance kidney care and related therapies," said Cristina Green, vice president of DCR.

Over the past 25 years, DCR has:

• Conducted 500+ clinical trials across 250+ research sites, with 8,900+ participants in the last 5 years.
• Engaged directly with every ESKD drug approved by the FDA.
• Launched the Alliance Site Network for early-stage CKD trials, with more than 50% of current trials focused on patients earlier in their care journey.

Expanding access through inclusive research
DaVita emphasizes outcomes research that addresses barriers faced by dialysis patients — an area often overlooked. In 2024, DCR implemented decentralized recruitment services to better include diverse patient populations in clinical trials. By leveraging DaVita's CKD electronic health record (EHR) system by Epic, this initiative has expanded trial access to underserved research locations.

For more information on DaVita' milestones over the last 25 years, visit DaVitaForward.com.

About DaVita
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2025, DaVita served approximately 283,100 patients at 3,175 outpatient dialysis centers, of which 2,662 centers were located in the United States and 513 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About. 

Media Contact
DaVita Newsroom
newsroom@davita.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-honors-25-years-of-clinical-advancement-in-chronic-disease-care-302539438.html

SOURCE DaVita

FAQ

What major milestones has DaVita Clinical Research (DCR) achieved in its 25-year history?

DCR has conducted 500+ clinical trials, published 180 manuscripts and 520 research abstracts, participated in every FDA-approved ESKD drug development, and contributed to COVID-19 vaccine trials.

How many patients and dialysis centers does DaVita (DVA) currently operate?

As of June 30, 2025, DaVita serves 283,100 patients through 3,175 outpatient dialysis centers, with 2,662 centers in the US and 513 centers across 13 other countries.

What significant research breakthrough did DaVita achieve in their 2017 study?

The 2017 study across 40 dialysis centers demonstrated that ClearGuard HD antimicrobial barrier caps significantly reduce bloodstream infections for patients with central venous catheters, improving patient outcomes at scale.

How is DaVita (DVA) improving access to clinical trials?

In 2024, DaVita implemented decentralized recruitment services and leverages their CKD electronic health record system to expand trial access to underserved research locations and include more diverse patient populations.

What is DaVita's latest research focus for 2025?

DaVita is presenting research at the American Society of Nephrology Kidney Week about the association between GLP-1 drugs and hospitalization rates for people with kidney failure.